Advantages of the novel mineralocorticoid receptor antagonist Finerenone in the treatment of diabetic kidney disease
10.3969/j.issn.1006-6187.2025.05.016
- VernacularTitle:非奈利酮在糖尿病肾脏疾病治疗中的优势
- Author:
Mingjie HE
1
;
Xiaochun CHEN
1
;
Rong XU
1
Author Information
1. 341000 赣州,赣南医科大学第一附属医院内分泌科
- Publication Type:Journal Article
- Keywords:
Finerenone;
Mineralocorticoid receptor antagonist;
Diabetic kidney disease;
Combination therapy
- From:
Chinese Journal of Diabetes
2025;33(5):396-400
- CountryChina
- Language:Chinese
-
Abstract:
[Summary]Diabetic kidney disease(DKD)caused a huge medical burden to society and has become an increasingly serious public health problem.Different from steroidal mineralocorticoid receptor antagonist,Finerenone,as a new non-steroidal mineralocorticoid receptor antagonist,has higher selectivity and effectiveness.It can effectively delay the progression of DKD through anti-inflammatory and anti-fibrosis effects,reduce urinary protein,and has a low incidence of hyperkalemia and a cardioprotective effect.This article summarizes the benefits of Finerenone in DKD,its advantages over other mineralocorticoid-receptor antagonists,and its efficacy in combination with other drugs for the treatment of DKD.
